Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED)

Phase 3

Completed

• Conditions: Major Depressive Disorder

• Registration Number: NCT00048607
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression

Detailed Description

The duration of treatment is 8 weeks.

Study Timeline

• Study Start: 2002-07-30
• Study First Submitted: 2002-11-04
• Study First Submitted QC: 2002-11-04
• Study First Posted: 2002-11-05
• Primary Completion: 2003-12-31
• Study Completion: 2003-12-31
• Status Verified: 2017-05
• Last Update Submitted: 2017-05-02
• Last Update Posted: 2017-05-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
HAMD-17 total score at week 8. Tolerability.	at week 8

Secondary Outcome Measures

Name	Time	Method
CGI-I Scale score at week 8 and Sheehan Disability Scale at week 8	at week 8